Research paperMedical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients
Section snippets
Background
The past two decades have witnessed a resurgence of interest in the therapeutic potential of cannabis, with several nations and jurisdictions developing regulations to allow for access to cannabis for medical purposes (Fischer, Murphy, Kurdyak, Goldner, & Rehm, 2015). One potential salutary consequence of these developments is the substitution of cannabis for other substances (Allsop et al., 2014, Lucas et al., 2013, Lucas et al., 2016). Indeed, examinations of jurisdictions with legal access
Design and methods
A password protected 107 question online cross-sectional survey was made available in French and English for a 2 week period in July 2015 to patients of Tilray—a licensed producer of cannabis. 1310 participants were notified of the opportunity to participate in this study via direct email to patients that had opted in to receive online communication from Tilray upon registration. Participants were compensated $10 credit for Tilray cannabis. The study was approved by Institutional Review Board
Findings
The survey was started by 301 participants, and completed by over 90% of respondents (n = 271). The 30 non-completers only filled out the demographic section of the study, and based on this information did not differ on age, gender, education, income or work status compared to those that completed the survey. The primary demographics of respondents corresponds with the greater Tilray patient population but was more male and Caucasian, single, disabled and of lower income than the general Canadian
Interpretation
The finding that patients using cannabis to treat pain-related conditions have a higher rate of substitution for opioids, and that patients self-reporting mental health issues have a higher rate of substitution for benzodiazepines and antidepressants has significant public health implications. In light of the growing rate of morbidity and mortality associated with these prescription medications (Bachhuber et al., 2014; Fischer, Rehm, Goldman, & Popova, 2008), cannabis could play a significant
Conclusions
The high rate of substitution for prescription drugs among patients with pain-related and mental health conditions suggests that medical cannabis may be an effective adjunct or substitute treatment to prescription drugs used to treat these conditions. Further research into the comparative efficacy of cannabis relative to front-line treatments for theses conditions is warranted, and longitudinal research would help elucidate the context of cannabis substitution effect, and the potential impact
Limitations
The relatively low response rate to the survey (21%) leaves open the possibility this could potentially be an unrepresentative sample. It is not possible to confirm the impact of cannabis substitution on quantity of use of prescription drugs, alcohol or illicit drug use. Additionally, all data regarding the cannabis substitution effect in this study were self-reported by patients and did not benefit from biological drug detection to confirm use or non-use of a substance. In light of this
Declaration of interest
This study was funded by Tilray, a federally authorised medical cannabis production and research company. Philippe Lucas is currently employed as Vice-President, Patient Research and Advocacy for Tilray; however, his compensation is not tied in any way to the outcomes of this study.
Zach Walsh is currently the Primary Investigator in a Tilray-sponsored randomized clinical trial of medical cannabis and PTSD, but he receives no financial compensation for that study nor for assisting with the
Acknowledgements
Funding for this study was provided by Tilray. We would like to thank all of the Tilray patients that have shared their thoughts and experiences with us, as well as Kim Crosby for assisting with some of the data analysis of this survey.
References (29)
- et al.
Changes in cigarette and alcohol use during cannabis abstinence
Drug and Alcohol Dependence
(2014) - et al.
Barriers to access for Canadians who use cannabis for therapeutic purposes
International Journal of Drug Policy
(2014) - et al.
Cannabidiol as a potential treatment for anxiety disorders
Neurotherapeutics
(2015) - et al.
Medication adherence: WHO cares?
Mayo Clinic Proceedings
(2011) - et al.
Medical marijuana programs—Why might they matter for public health and why should we better understand their impacts?
PMEDR
(2015) - et al.
Cannabis for therapeutic purposes: Patient characteristics, access, and reasons for use
International Journal of Drug Policy
(2013) - et al.
Cannabis for the management of pain: Assessment of safety study (COMPASS)
The Journal of Pain
(2015) - et al.
Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999–2010
JAMA Internal Medicine
(2014) - et al.
Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users
The American Journal of Drug and Alcohol Abuse
(2014) - et al.
Medical marijuana laws reduce prescription medication use in medicare part D
Health Affairs
(2016)